[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-346245-105":59,"doc-detail-346245-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","ds-3939a-first-disclosure-a-ta-muc1directed-antibodydrug-conjugate-with-broad-antitumor-activity","DS-3939a - First Disclosure - A TA-MUC1–Directed Antibody–Drug Conjugate with Broad Antitumor Activity","","Tumor-associated mucin-1 (TA-MUC1), a aberrantly glycosylated glycoform of MUC1 highly expressed across many epithelial cancers, is positioned as an attractive ADC target. The study describes DS-3939a, a novel TA-MUC1–directed antibody–drug conjugate using the potent DNA topoisomerase I inhibitor DXd, and evaluates its activity in preclinical in vitro and in vivo models. Clinical tumor tissue microarrays show TA-MUC1–positive staining across cancer types, with particularly high rates in bladder, lung, and breast cancers. In vitro studies confirm TA-MUC1-specific binding and induction of DNA damage and apoptosis in TA-MUC1–positive cells, while xenograft models demonstrate significant antitumor effects and tumor regression. Results suggest efficient payload delivery supports activity even after prior treatment with other ADCs, supporting ongoing phase I/II clinical evaluation (NCT05875168).",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/ds-3939a-first-disclosure-a-ta-muc1directed-antibodydrug-conjugate-with-broad-antitumor-activity/346245/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/ds-3939a-first-disclosure-a-ta-muc1directed-antibodydrug-conjugate-with-broad-antitumor-activity/346245.png","ImageObject",300,407,{"name":92,"@type":93},"Jiven","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is DS-3939a designed to target?","Question",{"text":112,"@type":113},"DS-3939a targets tumor-associated mucin-1 (TA-MUC1), a glycoform of MUC1 aberrantly glycosylated and predominantly observed in cancer cells.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does DS-3939a work in preclinical models?",{"text":117,"@type":113},"DS-3939a binds specifically to TA-MUC1–expressing cells and inhibits growth by inducing DNA damage and apoptosis, driven by its DNA topoisomerase I inhibitor payload (DXd).",{"name":119,"@type":110,"acceptedAnswer":120},"What preclinical evidence supports DS-3939a’s antitumor activity?",{"text":121,"@type":113},"It shows significant antitumor effects in TA-MUC1–positive cell line–derived and patient-derived xenograft models, including strong tumor regression in several xenograft models even after treatment with other cytotoxic ADCs.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},346245,1790313734,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099513958607,"https://ap-avatar.wpscdn.com/avatar/100002390cf8733938c?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778829742770036399","FIRST DISCLOSURE  \nDS-3939a: A TA-MUC1–Directed Antibody–Drug Conjugate with Broad Antitumor Activity  \nKohei Takano, Mayuko Yukiura, Kazuki Takahashi, Michiko Kitamura, Hiroko Okuno, Yoshinobu Shiose, Kokichi Honda, Kazunori Oyama, Makiko Yamada, Wataru Obuchi, Kazuyoshi Kumagai, Ken Sakurai, Riki Goto, Akiko Zembutsu, Takashi Kagari, Yuki Abe, and Toshinori Agatsuma†  \n|  |  | A |  | B | S |  | T | R |  | A |  | C | T |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 􀀶\u003Cbr>Tumor-associated mucin-1 (TA-MUC1) is a glycoform of the MUC1 protein that is aberrantly glycosylated and is primarily observed in cancer cells. TA-MUC1 is highly expressed in various human epithelial cancers, making it an attractive target for cancer therapies. In this study, we describe the development of DS-3939a, a novel TA-MUC1–targeting antibody–drug conjugate that utilizes the potent DNA topoisomerase I inhibitor DXd, and evaluation of its pharmacologic activity in preclinical in vitro and in vivo models. IHC of clinical tumor tissue microarrays of various cancer types exhibited positive staining for TA-MUC1 in a number of samples, with a particularly high positive rate in bladder, lung, and breast cancers. In vitro profiling of DS-3939a confirmed that it could specifically bind to TA-MUC1 and inhibit the growth of TA-MUC1–positive cancer cells by inducing DNA damage and apoptosis. DS-3939a also exhibited significant antitumor effects in multiple TA-MUC1–positive cell line– derived and patient-derived xenograft models. Moreover, DS- 3939a elicited strong tumor regression in several xenograft\u003Cbr>models even following treatment with other cytotoxic antibody–drug conjugates, likely through its efficient payload delivery. Overall, these data provide evidence for the potential utility of DS-3939a for the treatment of TA-MUC1–expressing tumors and support the rationale for the ongoing phase I/II clinical study (NCT05875168) .\u003Cbr>Humanized anti–TA-MUC1 IgG1 mAb\u003Cbr>Deruxtecan\u003Cbr>\u003Cbr>\u003Cbr>\u003Cbr>\u003Cbr>\u003Cbr>\u003Cbr>Cleavable tetrapeptide\u003Cbr>based linker Topoisomerase I inhibitor payload (DXd)\u003Cbr>DS-3939a\u003Cbr>DAR ≈ 8\u003Cbr>\u003Cbr>\u003Cbr>–100\u003Cbr>Broad antitumor activity of DS-3939a\u003Cbr>\u003Cbr>The figure on the lower left was created in BioRender. Takano, K. (2025) [https://BioRender.com/vl5uug4](https://BioRender.com/vl5uug4)\u003Cbr>Introduction\u003Cbr>Antibody–drug conjugates (ADC) are an emerging class of biotherapeutics that combine an antibody and cytotoxic payload via a chemical linker. This format allows the specific delivery of highly potent payloads to target cells, resulting in a wider therapeutic window compared with conventional chemotherapy. In fact, multiple ADCs have shown success in clinical trials. As of 2023, the FDA has approved a total of 11 ADCs (1), including trastuzumab deruxtecan (T-DXd), a novel HER2-targeting ADC, which has been approved by the FDA for multiple indications (2) . This number has now increased to 12 with the recent FDA approval of datopotamab deruxtecan (3) . As a result of the clinical success of multiple ADCs, including that of T-DXd, an even greater number of ADCs have recently entered clinical trials (4) . However, the majority of these\u003Cbr>Daiichi Sankyo Co., Ltd., Tokyo","cbCaii2hZe9EWTU2","https://ap.wps.com/l/cbCaii2hZe9EWTU2","pdf",24769887,14,"English","# Introduction\n## Antibody–drug conjugates and clinical context\n## ADC target diversity and unmet need\n## Rationale for glycoform-based targets\n## MUC1/TA-MUC1 as an ADC target","[{\"question\":\"What is DS-3939a designed to target?\",\"answer\":\"DS-3939a targets tumor-associated mucin-1 (TA-MUC1), a glycoform of MUC1 aberrantly glycosylated and predominantly observed in cancer cells.\"},{\"question\":\"How does DS-3939a work in preclinical models?\",\"answer\":\"DS-3939a binds specifically to TA-MUC1–expressing cells and inhibits growth by inducing DNA damage and apoptosis, driven by its DNA topoisomerase I inhibitor payload (DXd).\"},{\"question\":\"What preclinical evidence supports DS-3939a’s antitumor activity?\",\"answer\":\"It shows significant antitumor effects in TA-MUC1–positive cell line–derived and patient-derived xenograft models, including strong tumor regression in several xenograft models even after treatment with other cytotoxic ADCs.\"}]","DS-3939a - First Disclosure - A TA-MUC1–Directed Antibody–Drug Conjugate with Broad Antitumor Activity | PDF",1790060615,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/52fd738922b72ccd9a9fa485eb1eb384.webp",983,1315,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ff125fcca5043240dce5b3d24a679bcc.webp",982,1314,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/366af7111aace805fc85ade9ffeaf4eb.webp",981,1312,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9e8f730ffb53805ce7b8e7eb2ed6beba.webp",980,1311]